Beta Bionics, Inc. BBNX

Company Overview

Beta Bionics, Inc. is a medical device company focused on the development and commercialization of advanced automated insulin delivery systems for people with diabetes. The company operates within the medical technology, diabetes care, and digital health industries, with a core emphasis on integrating continuous glucose monitoring and insulin pump technology through adaptive algorithms. Its primary revenue driver is the iLet® Bionic Pancreas system, designed to simplify diabetes management by automating insulin dosing with minimal user input.

The company’s key customer segments include individuals with Type 1 diabetes and insulin-dependent Type 2 diabetes, as well as healthcare providers and payers involved in diabetes treatment. Beta Bionics is positioned around a clinically differentiated strategy: reducing cognitive burden for patients by eliminating the need for carbohydrate counting and complex pump settings. The company was founded in 2015, emerging from research conducted at Boston University, and transitioned from an academic research initiative into a commercial-stage medical device company following regulatory clearances and manufacturing scale-up.